Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trigger Point Injections vs Lidocaine Patch for Myofascial Pain in the ED
NCT05151510Phase 4Withdrawn
- Sponsor
- University of California, Irvine
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lidocaine 10% oropharyngeal spray in myofascial pain syndrome (MPS) (2 arms), sponsored by University of California, Irvine. Primary endpoint: Numerical Rating Scale of pain at 5 days. Planned start Nov 2021; status: withdrawn.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT05151510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151510.